#SFHS2603400ZOrder of February 4, 2026, Amending the List of Substitutable Biological Groups
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law clarifies that EYLEA 114.3 MG/ML injection solutions and pre-filled syringes do not have associated biosimilar drugs. Pharmacies need to be aware of this clarification, affecting how they substitute and inform prescribers and patients.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Clarifies that EYLEA does not have biosimilar drugs
- Impacts pharmacist substitution practices
- Requires pharmacists to inform prescribers and patients
Obligations
What this law requires
Pharmacies must recognize and maintain awareness that EYLEA 114.3 MG/ML injection solutions and pre-filled syringes have no associated biosimilar drugs available for substitution
Pharmacies must not substitute EYLEA 114.3 MG/ML injection solutions and pre-filled syringes with biosimilar alternatives, as none are authorized
Pharmacies must inform prescribers that EYLEA 114.3 MG/ML injection solutions and pre-filled syringes have no biosimilar substitutes available when relevant to prescription discussions
Pharmacies must inform patients that their EYLEA 114.3 MG/ML prescription cannot be substituted with a biosimilar alternative
Pharmacies must be aware that EYLEA 114.3 MG/ML injection solutions and pre-filled syringes have no associated biosimilar drugs and therefore cannot be substituted with biosimilars